Curated News
By: NewsRamp Editorial Staff
October 26, 2026
TransCode's TTX-MC138 Shows Safety and Efficacy Signals in Phase 1a Trial
TLDR
- TransCode Therapeutics reported TTX-MC138 met its Phase 1a safety endpoint with no dose-limiting toxicities, offering a first-mover advantage in RNA therapeutics for metastatic cancers.
- TTX-MC138 was administered every 28 days across four dose levels from 0.8 to 4.8 mg/kg, showing dose-dependent plasma exposure and disease stabilization in some patients.
- TransCode Therapeutics' TTX-MC138 trial results could lead to better treatments for advanced cancers, improving survival and quality of life for patients with limited options.
- TTX-MC138 targets microRNA-10b, a biomarker of metastasis, and its Phase 1a trial in advanced solid tumors showed promising disease stabilization.
Impact - Why it Matters
The positive Phase 1a results for TTX-MC138 are significant for TransCode Therapeutics and the broader oncology community. Demonstrating a clean safety profile with no dose-limiting toxicities and early signs of disease stabilization in advanced solid tumors is a critical milestone for a novel RNA-based therapeutic. This news matters because it validates the potential of targeting microRNA-10b, a key driver of metastasis, and could lead to a new treatment option for patients with high-risk cancers. For investors, the data supports continued clinical development and may enhance the company’s attractiveness in the competitive immuno-oncology space. Moreover, the successful application of RNA therapeutics in oncology could pave the way for similar approaches against other previously undruggable targets.
Summary
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage immuno-oncology and RNA therapeutics company, has announced positive clinical data from its Phase 1a trial of TTX-MC138 in patients with advanced solid tumors. The results were presented in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study is evaluating the safety, tolerability, pharmacokinetics, antitumor activity, and exploratory biomarkers of TTX-MC138, which was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. Additionally, the company reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138.
TTX-MC138 is TransCode’s lead therapeutic candidate, designed to treat metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. The full press release can be viewed at https://ibn.fm/g3E2F. For the latest news and updates relating to RNAZ, visit the company’s newsroom at https://ibn.fm/RNAZ.
The announcement was distributed by InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. This broad reach helps clients achieve unparalleled recognition and brand awareness.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode's TTX-MC138 Shows Safety and Efficacy Signals in Phase 1a Trial
